International Stem Cell (ISCO) Stock Price, News & Analysis

Company Overview

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations. By licensing its cell-based technology, ISCO aims to foster collaboration across the scientific community and accelerate the development of cell therapy and drug discovery platforms worldwide.

Beyond its core stem cell activities, the company markets consumer skin care products under the Lifeline® brand. Leveraging its expertise in human cell biology, ISCO’s skin care portfolio features anti-aging formulations based on cell-conditioned media, peptides and growth factors designed to support skin rejuvenation. These products are distributed through e-commerce channels and selected retail partners in North America, Europe and Asia.

Founded in 2008 and headquartered in Carlsbad, California, International Stem Cell Corporation was co‐founded by Dr. Michael D. West, a veteran in the field of regenerative medicine. The company operates research facilities in California and Australia, reflecting its commitment to global collaboration and the advancement of parthenogenetic stem cell science. Through ongoing R&D efforts and strategic partnerships, ISCO seeks to translate its proprietary hpSC technology into clinical and commercial successes in the emerging cell therapy market.

Key Stats

• Today's Range: $0.17 to $0.18
• 50-Day Range: $0.14 to $0.18
• 52-Week Range: $0.11 to $0.27
• Volume: 999 shs
• Average Volume: 1,840 shs
• Market Capitalization: $1.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

International Stem Cell Stock Analysis - MarketRank™

International Stem Cell scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for International Stem Cell.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of International Stem Cell is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of International Stem Cell is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.47% of the float of International Stem Cell has been sold short.

Short Interest Ratio / Days to Cover

International Stem Cell has a short interest ratio ("days to cover") of 12.41, which indicates bearish sentiment.

Change versus previous month

Short interest in International Stem Cell has recently increased by 108.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

International Stem Cell does not currently pay a dividend.

Dividend Growth

International Stem Cell does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for International Stem Cell this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, International Stem Cell insiders have not sold or bought any company stock.

Percentage Held by Insiders

83.46% of the stock of International Stem Cell is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

International Stem Cell has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 3/30/2026
• Today: 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ISCO
• CIK: 1355790
• Web: www.internationalstemcell.com
• Phone: (760) 940-6383
• Fax: 760-476-0600
• Employees: 30
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$420 thousand
• Net Margins: -5.27%
• Pretax Margin: -4.59%
• Return on Equity: N/A
• Return on Assets: -9.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.74
• Quick Ratio: 0.41

Sales & Book Value

• Annual Sales: $9.10 million
• Price / Sales: 0.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.51) per share
• Price / Book: -0.33

Miscellaneous

• Outstanding Shares: 8,000,000
• Free Float: 1,324,000
• Market Cap: $1.36 million
• Optionable: Not Optionable
• Beta: 0.06